NASDAQ:CYTR - CytRx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.74 -0.02 (-2.65 %)
(As of 03/22/2019 06:00 AM ET)
Previous Close$0.75
Today's Range$0.7239 - $0.7630
52-Week Range$0.33 - $2.05
Volume140,719 shs
Average Volume211,080 shs
Market Capitalization$24.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Receive CYTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTR
CUSIPN/A
Phone310-826-5648

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$100,000.00
Book Value$0.66 per share

Profitability

Net Income$-34,980,000.00

Miscellaneous

Employees20
Market Cap$24.73 million
Next Earnings Date3/25/2019 (Estimated)
OptionableOptionable

CytRx (NASDAQ:CYTR) Frequently Asked Questions

What is CytRx's stock symbol?

CytRx trades on the NASDAQ under the ticker symbol "CYTR."

When did CytRx's stock split? How did CytRx's stock split work?

Shares of CytRx reverse split before market open on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.

How were CytRx's earnings last quarter?

CytRx Co. (NASDAQ:CYTR) announced its quarterly earnings data on Monday, August, 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.08. View CytRx's Earnings History.

When is CytRx's next earnings date?

CytRx is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for CytRx.

What price target have analysts set for CYTR?

1 analysts have issued 1-year price targets for CytRx's shares. Their forecasts range from $5.00 to $5.00. On average, they expect CytRx's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 580.3% from the stock's current price. View Analyst Price Targets for CytRx.

What is the consensus analysts' recommendation for CytRx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytRx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytRx.

What are Wall Street analysts saying about CytRx stock?

Here are some recent quotes from research analysts about CytRx stock:
  • 1. According to Zacks Investment Research, "CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies. " (1/7/2019)
  • 2. HC Wainwright analysts commented, "Our price target is based on a composite valuation assessment that ascribes: (1) $105M to the future royalty streams from sales of aldoxorubicin, to which we assign a 60% probability of success and 12% discount rate; and (2) $55M to the LADR portfolio of candidates, which includes the companion diagnostic platform." (11/5/2018)

Has CytRx been receiving favorable news coverage?

Media coverage about CYTR stock has been trending somewhat positive on Friday, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CytRx earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future.

Who are some of CytRx's key competitors?

What other stocks do shareholders of CytRx own?

Who are CytRx's key executives?

CytRx's management team includes the folowing people:
  • Mr. Steven A. Kriegsman, Chairman & CEO (Age 77)
  • Mr. John Y. Caloz, Chief Financial Officer (Age 67)
  • Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 56)
  • Mr. Eric L. Curtis M.B.A., Pres & COO (Age 50)

Who are CytRx's major shareholders?

CytRx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.27%). View Institutional Ownership Trends for CytRx.

Which institutional investors are buying CytRx stock?

CYTR stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for CytRx.

How do I buy shares of CytRx?

Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $0.7350.

How big of a company is CytRx?

CytRx has a market capitalization of $24.73 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-34,980,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. CytRx employs 20 workers across the globe.

What is CytRx's official website?

The official website for CytRx is http://www.cytrx.com.

How can I contact CytRx?

CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]


MarketBeat Community Rating for CytRx (NASDAQ CYTR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel